High Bone Density in Hyperandrogenic Women: Effect of Gonadotropin-Releasing Hormone Agonist Alone or in Conjunction with Estrogen-Progestin Replacement

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 2, 1996, Pages 646-651

  Simberg, Niklas ^a   Tiitinen, Aila ^a   Silfvast, Annuli ^b   Viinikka, Lasse ^a   Ylikorkala, Olavi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Medix Clinical Laboratories   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; GONADORELIN AGONIST;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADULT; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HIRSUTISM; HUMANS; HYDROXYPROLINE; HYPERANDROGENISM; MEDROXYPROGESTERONE 17-ACETATE; TESTOSTERONE;

EID: 0030050342     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.81.2.8636283     Document Type: Article

References (43)

1. Emmi AM. 1993 The use of GnRH agonists in the medical therapy of endometriosis in the woman with pain. Semin Reprod Endocrinol. 11:119-126.
2. Friedman AJ. 1993 Treatment of uterine myomas with GnRH agonists. Semin Reprod Endocrinol. 11:154-161.
3. Chang RJ, Laufer LR, Meldrum DR, et al. 1983 Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 56:897-903.
4. Tiitinen A, Simberg N, Stenman U-H, Ylikorkala O. 1994 Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist- induced androgen suppression in treatment of hirsutism. J Clin Endocrinol Metab. 79:447-451.
5. Fogelman I. 1992 Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril. 57:715-724.
6. Gallagher JC. 1993 Effect of gonadotropin-releasing hormone agonists on bone metabolism. Semin Reprod Endocrinol. 11:201-208.
7. Dawood MY. 1994 Hormonal therapies for endometriosis: implications for bone metabolism. Acta Obstet Gynecol Scand Suppl. 159:22-34.
8. Buchanan JR, Hospodar P, Myers C, Leuenberger P, Demers LM. 1988 Effect of excess endogenous androgens on bone density in young women. J Clin Endocrinol Metab. 67:937-943.
9. Adashi EY. 1994 Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Human Reprod Update. 9:1380-1397.
10. Riis BJ, Christiansen C, Johansen JS, Jacobson J. 1990 Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonist? J Clin Endocrinol Metab. 70:920-924.
11. Surrey ES, Judd HL. 1992 Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. J Clin Endocrinol Metab. 75:558-563.
12. Friedman AJ, Daly M, Juneau-Norcross M, et al. 1993 A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J Clin Endocrinol Metab. 76:1439-1445.
13. Ferriman D, Gallwey JD. 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 21:1440-1447.
14. Couzinet B, Le Strat N, Brailly S, Schaison G. 1986 Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. J Clin Endocrinol Metab. 63:1031-1035.
15. De Boer H, Blok GJ, Van Lingen A., et al. 1994 Consequenses of childhood-onset growth hormone deficiency for adult bone mass. J Bone Mineral Res. 9:1319-1326.
16. Epstein S. 1988 Serum and urinary markers of bone remodeling: Assessment of bone turnover. Endocrine Rew. 9:437-449.
17. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. 1993 Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem. 39:635-640.
18. Podenphant J, Larsen N-E, Christiansen C. 1984 An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta. 142:145-148.
19. Rittmaster RS. 1993 Use of Gonadotropin releasing hormone agonists in the treatment of hyperandrogenism. Clin Obstet Gynecol. 36:679-689.
20. Raisz LG. 1993 Bone cell biology: New approaches and unanswered questions. J Bone Mineral Res 8 (suppl 2):S457-S465.
21. Finklestein JS, Klibanski A, Neer RM, et al. 1987 Osteoporosis in men with idiopathic hypogonadotrophic hypogonadism. Ann Intern Med. 106:354-361.
22. Chesnut CH, Ivey JL, Gruber HE, et al. 1983 Stanozolol in postmenopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action. Metabolism. 32:571-580.
23. Dixon JE, Rodin A, Murby B, Chapman MG, Fogelman I. 1989 Bone mass in hirsute women with androgen excess. Clin Endocrinol. 30:271-277.
24. Steinberg KK, Freni-Titulaer LW, DePuey EG, et al. 1989 Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab. 69:533-539.
25. Colvard DS, Eriksen EF, Keeting PE, et al. 1989 Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA. 86:854-857.
26. Liebherr M, Grosse B. 1994 Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem. 269:7217-7223.
27. Lindsay R, Aitken JM, Anderson JB, et al. 1976 Long-term prevention of postmenopausal osteoporosis by oestrogen treatment. Lancet i:1038-41.
28. Turner RT, Riggs BL, Spelsberg TC. 1994 Skeletal effects of estrogen. Endocrine Rev. 15:275-300.
29. Homburg R, Pariente C, Lunenfeld B, Jacobs HS. 1992 The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Human Reprod. 7:1379-1383.
30. Giudice LC, Chandrasekher YA, Cataldo NA. 1993 The potential roles of intraovarian peptides in normal and abnormal mechanisms of reproductive physiology. Curr Opin Obstet Gynec. 5:350-359.
31. Raisz LG. 1988 Local and systemic factors in the pathogenesis of osteoporosis. New Engl J Med. 318:818-828.
32. Canalis E, McCarthy T, Centrella M. 1988 Growth factors and the regulation of bone remodeling. J Clin Invest. 81:277-281.
33. Canalis E. 1994 Editorial: Skeletal Growth factors and ageing. J Clin Endocrinol Metab. 78:1009-1010.
34. Leather AT, Studd JWW, Watson NR, Holland EFN. 1993 The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy. Obstet Gynecol. 81:104-107.
35. Dodin S, Lemay A, Maheux R, et al. 1991 Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol. 77:410-415.
36. Rock JA, Truglia JA, Caplan RJ, et al. 1993 Zoladex (Goserelin acetate implant) in the treatment of endometriosis: A randomized comparison with danazol. Obstet Gynecol. 82:198-205.
37. Christiansen C, Christensen MS, Transbol I. 1981 Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet, February. 28:459-61.
38. Christiansen C, Riis BJ, Rodbro P. 1987 Prediction of rapid bone loss in postmenopausal women. Lancet, May. 16:1105-1108.
39. Eyre D. 1992 Editorial: New Biomarkers of bone resorption. J Clin Endocrinol Metab. 74:470A-470C.
40. Seibel MJ, Cosman F, Shen V, et al. 1993 Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Mineral Res. 8:881-889.
41. Roux C, Pelissier C, Listrat V, et al. 1993 GnRH agonist-induced bone loss and use of nasal calcitonin. J Bone Mineral Res 8:Suppl 1:S151.
42. Finkelstein JS, Klibanski A, Schaefer EH, et al. 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med. 331:1618-1623.
43. Surrey ES, Fournet N, Voigt B, Judd HL. 1993 Effect of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: A preliminary report. Obstet Gynecol. 81:581-586.